• Chong-Yang Jia, Yan He, Shi-Nan Wu, Yan-Ting He, and Ying Wang.
• Department of General Surgery, the Second Hospital of Lanzhou, Lanzhou, China.
• Medicine (Baltimore). 2022 Nov 18; 101 (46): e31728e31728.

BackgroundMicrorNA-144 (MiR-144) has been shown to be an attractive prognostic tumor biomarker and play a fundamental role in various cancers, However, the conclusion was inconsistency. The aim of this study was to identify the prognostic role of miR-144 in cancers.MethodsRelevant studies were searched in PubMed, EMBASE and Web of Science up to April 20, 2022. Hazard ratios (HR), odds ratio (OR) and 95% confidence intervals were pooled from the selected studies.ResultsA total of 15 articles involving 1846 participants fulfilled the inclusion criteria. The results revealed that low miR-144 expression was significantly associated with favorable overall survival (HR: 0.68, 95% confidence interval [CI]: 0.53-0.88) in various cancers. Low miR-144 expression had better predictive value in patients with urinary system cancer (HR: 0.48, 95% CI: 0.35-0.64). In addition, low miR-144 expression was associated with tumor diameter (big vs small) (OR: 1.69, 95% CI: 1.08-2.75), tumor stage (III-IV vs I-II) (OR: 2.52, 95% CI: 3.76-8.14) and invasion depth (T3 + T4 vs T2 + T1) (OR: 3.24, 95% CI: 1.72-4.89).ConclusionmiR-144 may serve as a prognostic biomarker in cancers.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

8 keywords...

hide…